Correlating Irinotecan and Capecitabine Treatment for Colorectal Cancer to Gene Expression, Polymorphisms, and Clinical Outcomes
Indiana University-Purdue University Indianapolis (IUPUI) === Colorectal cancer is the third most common type of cancer and the third most common cause of cancer-related mortality. There are three types of treatment available to patients, either individually or in combination. Treatments are radiati...
Main Author: | Hinkle, David T., IV. |
---|---|
Other Authors: | Harrington, Maureen A. |
Language: | en |
Published: |
2011
|
Subjects: | |
Online Access: | https://hdl.handle.net/1805/2510 |
Similar Items
-
Human carboxylesterase 2 splice variants: expression, activity, and role in the metabolism of irinotecan and capecitabine
by: Schiel, Marissa Ann
Published: (2009) -
Predictors of Irinotecan Toxicity and Efficacy in Treatment of Metastatic Colorectal Cancer
by: Adam Paulík, et al.
Published: (2012-01-01) -
CAPECITABINE AND IRINOTECAN AS FIRST- LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2010-11-01) -
UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study
by: Hideki Matsuoka, et al.
Published: (2020-08-01) -
The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis
by: Xingfa Huo, et al.
Published: (2021-01-01)